Arsil%2525252525252525252520dx

# Arsil DX (Dextromethorphan HBr) ## Overview Arsil DX is a brand-name formulation containing Dextromethorphan Hydrobromide, a centrally-acting non-opioid antitussive. It acts on the sigma-1 receptor and the cough center in the medulla to elevate the cough threshold. ## Primary Indications Temporary relief of non-productive cough due to minor throat and bronchial irritation (associated with the common cold or inhaled irritants). ## Adult Dosing Standard dose: 10–20 mg orally every 4 hours or 30 mg every 6–8 hours as needed. Maximum dose: 120 mg per 24 hours. ## Pediatric Dosing *Note: Use is generally discouraged in children under 4 years of age due to lack of efficacy and safety concerns; follow local institutional protocols.* * **Children 6–12 years:** 5–10 mg orally every 4 hours or 15 mg every 6–8 hours. Maximum 60 mg/24 hours. * **Children 4–6 years:** 2.5–5 mg orally every 4 hours or 7.5 mg every 6–8 hours. Maximum 30 mg/24 hours. ## Dose Adjustments * **Hepatic Impairment:** Reduce dosage or increase dosing interval in patients with severe hepatic impairment, as dextromethorphan is extensively metabolized in the liver. * **Renal Impairment:** No specific adjustment guidelines exist; use with caution. ## Contraindications * Known hypersensitivity to dextromethorphan. * Current or recent (within 14 days) use of Monoamine Oxidase Inhibitors (MAOIs). * Chronic cough associated with asthma, emphysema, or smoking. ## Adverse Effects * **Common:** Dizziness, drowsiness, nausea, vomiting, stomach pain. * **Serious:** Serotonin syndrome (when used with serotonergic agents), respiratory depression (rare, usually associated with overdose), psychosis, and visual hallucinations at supratherapeutic doses. ## Key Drug Interactions * **MAOIs:** Risk of severe, potentially fatal serotonin syndrome. * **SSRIs/SNRIs/TCAs:** Increased risk of serotonin syndrome due to additive serotonergic effects. * **CNS Depressants (Alcohol, sedatives):** Potential additive sedative effects. * **CYP2D6 Inhibitors (e.g., fluoxetine, quinidine):** May increase plasma concentrations of dextromethorphan, increasing the risk of adverse effects. ## Monitoring * Monitor for cough frequency and duration. * Assess for signs of serotonin syndrome (confusion, tachycardia, diaphoresis, tremor, hyperreflexia). * Discontinue and seek medical evaluation if cough persists for >7 days, is accompanied by high fever, rash, or persistent headache. ## Clinical Pearls * Dextromethorphan is a stereoisomer of the codeine analog levorphanol but lacks analgesic, sedative, or addictive properties at therapeutic doses. * "DX" formulations often contain other ingredients (e.g., guaifenesin, antihistamines); always verify the product label to prevent accidental overdose from multicomponent combinations. * Abuse potential exists; high doses produce dissociative states similar to ketamine or PCP. *** **Educational Disclaimer:** This information is for educational purposes only. Always consult the official package insert or your institution's clinical pharmacy database and prescribing protocols to verify current dosing, contraindications, and drug-specific safety information before administration.